From: Treatment outcomes in patients with acute thromboembolic occlusion of the superior mesenteric artery
Variables | All patients(n = 62) | Endovascular first(n = 21) | Open surgery first(n = 37) | Conservative treatment(n = 4) | pa |
---|---|---|---|---|---|
Age, median(IQR), y | 69(58–79) | 65(55–79) | 71(61–80) | 65(54–74) | 0.444 |
Male, % | 55 | 48 | 58 | 75 | 0.600 |
Active smoking, % | 29 | 14 | 38 | 25 | 0.193 |
Comorbidities, % | |||||
Hypertension, % | 69 | 86 | 59 | 75 | 0.095 |
Diabetes mellitus, % | 34 | 33 | 38 | 0 | 0.269 |
Atrial fibrillation, % | 66 | 67 | 65 | 75 | 1.000 |
Coronary artery disease, % | 35 | 48 | 32 | 0 | 0.097 |
Congestive heart failure, % | 13 | 10 | 14 | 25 | 0.567 |
Chronic renal insufficiency, % | 13 | 14 | 11 | 25 | 0.459 |
ASA > 3 | 27 | 5 | 41 | 25 | 0.009 |
Duration of symptoms onset to treatment, median (IQR), h | 48(18–120) | 24(11–120) | 48(24–120) | 132(30–168) | 0.214 |
Abdominal pain, % | 98 | 100 | 97 | 100 | 1.000 |
Emesis, % | 61 | 67 | 62 | 25 | 0.376 |
Diarrhea, % | 35 | 33 | 35 | 50 | 0.833 |
Hematochezia, % | 23 | 10 | 32 | 0 | 0.094 |
WBC count, mean ± SD, × 103/dL | 15 ± 9 | 13 ± 7 | 17 ± 10 | 14 ± 8 | 0.278 |
Neutrophil ratio median (IQR), % | 87(81–90) | 87(74–89) | 87(82–91) | 87(68–92) | 0.676 |
Urea, mean ± SD, mmol/L | 9 ± 5 | 8 ± 6 | 9 ± 4 | 11 ± 9 | 0.679 |
Creatinine, mean ± SD, umol/L | 107 ± 117 | 126 ± 182 | 92 ± 35 | 121 ± 74 | 0.592 |
Potassium, mean ± SD, mg/dL | 4.0 ± 0.6 | 3.8 ± 0.6 | 4.1 ± 0.5 | 4.2 ± 0.8 | 0.231 |
Alanine transaminase, median (IQR), U/L | 17(13–30) | 15(11.3–28.0) | 21.0(12.8–37.3) | 20.5(14.0-2649.8) | 0.449 |
Aspartate transaminase, median (IQR), U/L | 25(17–48) | 22.4(14.4–37.2) | 32.4(18.7–54.5) | 20.0(16.4-7284.3) | 0.294 |
Lactate, median (IQR), mmol/L | 3.3 ± 2.2 | 2.5 ± 2.5 | 3.6 ± 2.2 | 1.5 ± 0.5 | 0.175 |
D-dimer (IQR), mg/L | 2.3(1.1–4.5) | 2.3(1.7–8.5) | 2.3(1.1-4.0) | 0.9(0.3-8.0) | 0.360 |
Occlusion segmentation of SMA | |||||
S1, % | 21 | 24 | 16 | 50 | 0.224 |
S2, % | 30 | 42 | 27 | 25 | 0.748 |
S3, % | 13 | 19 | 11 | 0 | 0.684 |
S1-S2, % | 10 | 0 | 16 | 0 | 0.138 |
S2-S3, % | 21 | 15 | 27 | 25 | 0.259 |
S1-S3, % | 2 | 5 | 0 | 0 | 0.403 |
S1-S2-S3, % | 3 | 5 | 3 | 0 | 1.000 |